JP2009527463A5 - - Google Patents

Download PDF

Info

Publication number
JP2009527463A5
JP2009527463A5 JP2008550463A JP2008550463A JP2009527463A5 JP 2009527463 A5 JP2009527463 A5 JP 2009527463A5 JP 2008550463 A JP2008550463 A JP 2008550463A JP 2008550463 A JP2008550463 A JP 2008550463A JP 2009527463 A5 JP2009527463 A5 JP 2009527463A5
Authority
JP
Japan
Prior art keywords
compound
compound according
alkyl
cancer
aralkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008550463A
Other languages
English (en)
Japanese (ja)
Other versions
JP5202332B2 (ja
JP2009527463A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/001127 external-priority patent/WO2007082104A2/en
Publication of JP2009527463A publication Critical patent/JP2009527463A/ja
Publication of JP2009527463A5 publication Critical patent/JP2009527463A5/ja
Application granted granted Critical
Publication of JP5202332B2 publication Critical patent/JP5202332B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008550463A 2006-01-13 2007-01-16 がんの治療のための化合物および方法 Expired - Fee Related JP5202332B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75921806P 2006-01-13 2006-01-13
US60/759,218 2006-01-13
US76300806P 2006-01-26 2006-01-26
US60/763,008 2006-01-26
PCT/US2007/001127 WO2007082104A2 (en) 2006-01-13 2007-01-16 Compounds and methods for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2009527463A JP2009527463A (ja) 2009-07-30
JP2009527463A5 true JP2009527463A5 (US20040106767A1-20040603-C00005.png) 2010-03-04
JP5202332B2 JP5202332B2 (ja) 2013-06-05

Family

ID=38158019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008550463A Expired - Fee Related JP5202332B2 (ja) 2006-01-13 2007-01-16 がんの治療のための化合物および方法

Country Status (10)

Country Link
US (2) US8222440B2 (US20040106767A1-20040603-C00005.png)
EP (1) EP1979368B1 (US20040106767A1-20040603-C00005.png)
JP (1) JP5202332B2 (US20040106767A1-20040603-C00005.png)
KR (2) KR20130129316A (US20040106767A1-20040603-C00005.png)
CN (2) CN104109177A (US20040106767A1-20040603-C00005.png)
AU (1) AU2007204831B2 (US20040106767A1-20040603-C00005.png)
CA (1) CA2636793C (US20040106767A1-20040603-C00005.png)
HK (2) HK1130804A1 (US20040106767A1-20040603-C00005.png)
IL (3) IL192738A0 (US20040106767A1-20040603-C00005.png)
WO (1) WO2007082104A2 (US20040106767A1-20040603-C00005.png)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0821002A2 (pt) * 2007-12-12 2015-06-16 Ziopharm Oncology Inc Compostos e métodos para o tratamento de câncer
DK3388111T3 (da) * 2008-08-20 2021-12-06 Solasia Pharma K K Organoarsenforbindelse til behandlingen af kræft
KR20160086960A (ko) * 2013-12-05 2016-07-20 솔레이지아 파마 가부시키가이샤 암 치료를 위한 화합물 및 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1964557B1 (en) 1997-11-10 2013-01-02 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
WO2003057012A2 (en) * 2002-01-07 2003-07-17 Board Of Regents, The University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
TW201440760A (zh) * 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物

Similar Documents

Publication Publication Date Title
RU2441005C2 (ru) Новые пиразолопиримидины как ингибиторы циклинзависимых киназ
JP2008506710A5 (US20040106767A1-20040603-C00005.png)
JP2012153722A5 (US20040106767A1-20040603-C00005.png)
JP2020532532A5 (US20040106767A1-20040603-C00005.png)
JP2017538677A5 (US20040106767A1-20040603-C00005.png)
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
JP2019535744A5 (US20040106767A1-20040603-C00005.png)
JP2008528671A5 (US20040106767A1-20040603-C00005.png)
JP2014506913A5 (US20040106767A1-20040603-C00005.png)
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
JP2018504378A5 (US20040106767A1-20040603-C00005.png)
JP2013544846A5 (US20040106767A1-20040603-C00005.png)
JP2016529324A5 (US20040106767A1-20040603-C00005.png)
JP2017511321A5 (US20040106767A1-20040603-C00005.png)
JP2016519653A5 (US20040106767A1-20040603-C00005.png)
JP2010241830A5 (US20040106767A1-20040603-C00005.png)
JP2016040288A5 (US20040106767A1-20040603-C00005.png)
JP2015520753A5 (US20040106767A1-20040603-C00005.png)
JP2015508103A5 (US20040106767A1-20040603-C00005.png)
JP2015512943A5 (US20040106767A1-20040603-C00005.png)
JP2013518089A5 (US20040106767A1-20040603-C00005.png)
JP2019516766A5 (US20040106767A1-20040603-C00005.png)
JP2015512398A5 (US20040106767A1-20040603-C00005.png)
JP2017526677A5 (US20040106767A1-20040603-C00005.png)
JP2017526662A5 (US20040106767A1-20040603-C00005.png)